Study identification

PURI

https://redirect.ema.europa.eu/resource/16992

EU PAS number

EUPAS3330

Study ID

16992

Official title and acronym

Adherence to disease modifying drugs of patients with multiple sclerosis (ADAPIMS)

DARWIN EU® study

No

Study countries

Germany

Study description

Objective is to evaluate the adherence of patients to disease modifying drugs

Study status

Finalised
Research institutions and networks

Institutions

Deutsches Arzneiprüfungsinstitut e.V. (DAPI)

Contact details

Johanna Werning

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

DAPI, TU Dresden
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable